News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN(R) for the Treatment of Prostate Cancer (PR Newswire) ...As a secondary endpoint, the Company is measuring tumor response at both the treated lesion as well as remote metastatic sites....... cancer cells derived from many types of cancer including breast, prostate, pancreatic and brain tumours.... - Oct 11 9:05 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/011011/to276_1.html

Posted on: 10/11/2001

"Yahoo - Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN(R) for the Treatment of Prostate Cancer"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
ONC.TO
ONCY
9.45
6
0.75
0.55
delayed 20 mins - disclaimer
Quote Data provided by Reuters


Thursday October 11, 9:05 am Eastern Time

Press Release

SOURCE: Oncolytics Biotech Inc.

Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN(R) for the Treatment of Prostate Cancer

CALGARY, Oct. 11 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSE: ONC - news); (NASDAQ: ONCY - news) announced today that it has received approval from Health Canada to initiate a clinical study to evaluate the efficacy of REOLYSIN® for the treatment of T2 prostate cancer.

"We are very excited to be given approval to enter our first clinical study with efficacy as a primary endpoint," said Dr. Brad Thompson. "We expect this to be the first of a number of studies to be initiated in the near future that will build upon the results of a Phase I clinical study."

REOLYSIN® is the formulation of the reovirus that is a potential therapeutic for a broad range of cancers in humans. Oncolytics is in the process of completing enrolment in its Phase I clinical trial for REOLYSIN® and filed an application for the prostate clinical study on the basis of the early results from the Phase I trial. The Phase I trial is designed to determine the safety and tolerance of REOLYSIN® when administered to late stage cancer patients. As a secondary endpoint, the Company is measuring tumor response at both the treated lesion as well as remote metastatic sites. Oncolytics expects to release a complete review of these results after completion of the study. Following discussions with clinical experts, the Company broadened the protocol of its initial application for T2A prostatic disease to T2, which will improve the ability of the Company to enrol patients.

This T2 prostate cancer trial is intended to evaluate the efficacy of intra-tumoral administration of REOLYSIN® for the treatment of cancer that is restricted to the prostate gland. Patients will receive a single injection of REOLYSIN® and will be monitored for approximately three weeks, at which time the prostate may be surgically removed. The primary efficacy endpoint will be the response rate as measured by PSA levels, MRI, and pathological examination of the tumor. The trial is expected to enrol a total of 45 patients in three or more clinical sites across Canada.

Cancer of the prostate is one of the most common cancers in men, representing approximately one-third of all male cancers in western society. It is second to lung cancer as the leading cause of cancer deaths in men. There are an estimated 16,600 new cases of prostate cancer in Canada and the American Cancer Society estimates that there will be 198,100 new cases in the US in 2001.

About Oncolytics Biotech

Oncolytics is a Calgary-based biotechnology company focused on the development of the human Reovirus (REOLYSIN®), as a potential cancer therapeutic. Oncolytics researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells derived from many types of cancer including breast, prostate, pancreatic and brain tumours. Research has also yielded successful cancer treatment results in a number of animal models. In November of 2000, Oncolytics entered into a worldwide licensing agreement with Pfizer Inc. for the development and marketing of the reovirus for animal health applications.

To find out more about Oncolytics Biotech Inc. (TSE: ONC - news), (NASDAQ: ONCY - news), visit the Company's website at www.oncolyticsbiotech.com.

This press release contains forward looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements, including the company's ability to broaden its investor base in the United States, the potential of REOLYSIN® as a cancer therapeutic, and the belief that Ras pathway has broad potential in the treatment of many cancers, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue Research and Development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.

SOURCE: Oncolytics Biotech Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes
and News:
Related News Categories: biotech, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740